The HFE Knockout NCI-H1975 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the human NCI-H1975 lung adenocarcinoma cell line. This product provides a heterogeneous pool of cells carrying targeted disruption of the HFE gene, generated without single-cell cloning, and serves as a robust loss-of-function model for interrogating iron regulatory mechanisms in cancer biology. The polyclonal format preserves population-level genetic diversity, enabling physiologically relevant functional studies.
NCI-H1975 is a well-characterized epithelial cell line isolated from a nonsmoker female with non-small cell lung cancer. It endogenously expresses activating EGFR L858R and resistance-associated T790M mutations, making it a widely employed model for studying acquired resistance to first- and second-generation EGFR tyrosine kinase inhibitors (TKIs). Its defined signaling background and tumorigenic properties provide a clinically relevant platform for exploring iron metabolism and ferroptosis in lung adenocarcinoma.
HFE encodes an MHC class I-like protein that governs systemic iron balance by engaging transferrin receptors (TFR1 and TFR2) and modulating the BMP-SMAD pathway to regulate hepcidin (HAMP) transcription. Normally, HFE competes with transferrin for TFR1 binding and, upon iron sensing, promotes formation of a complex involving TFR2, the coreceptor hemojuvelin (HJV), and ALK2/BMP receptors, leading to SMAD1/5/8 phosphorylation and induction of hepcidin, which triggers ferroportin degradation to limit iron absorption. CRISPR/Cas9-mediated HFE disruption abolishes these interactions, attenuating BMP-SMAD-mediated hepcidin expression and resulting in dysregulated iron uptake and potential intracellular iron accumulation, recapitulating features of hereditary hemochromatosis.
In the context of NCI-H1975 lung adenocarcinoma, HFE knockout holds particular significance given emerging connections between iron metabolism, oncogenic signaling, and drug tolerance. Elevated intracellular iron levels may exacerbate oxidative stress and influence sensitivity to ferroptosis, a form of regulated cell death being explored to overcome EGFR-TKI resistance. This polyclonal model therefore enables dissection of how HFE loss-of-function-dependent iron dysregulation intersects with EGFR-mutant signaling networks, tumor progression, and therapeutic vulnerability.
Researchers can employ these cells in diverse experimental workflows, including western blotting for HFE, total and phospho-SMAD1/5/8, and downstream targets; RT-qPCR for HAMP transcript levels; and functional assays such as iron staining, ferritin ELISA, transferrin receptor (TFR1) flow cytometry, and radioactive or fluorescence-based iron uptake measurements. Additional protocols like cell viability assays under iron chelation (e.g., deferoxamine) or ferroptosis induction (e.g., erastin), and co-immunoprecipitation of HFE with TFR1, further validate disrupted interactions. These applications support research into iron metabolism, hereditary hemochromatosis modeling, and iron dependency in cancer drug resistance. For detailed technical specifications, please contact Ascent Research.
